Product
Seasonal Influenza Vaccine
4 clinical trials
4 indications
Indication
Multiple SclerosisIndication
Relapsing-RemittingIndication
Seasonal InfluenzaIndication
COVID-19Clinical trial
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and OlderStatus: Completed, Estimated PCD: 2024-01-05
Clinical trial
A Phase 3b, Multicenter, Open-label Study to Evaluate the Immune Response to, and the Safety of, Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Oral Ozanimod Compared to Non-pegylated Interferon (IFN)-β or No Disease Modifying TherapyStatus: Completed, Estimated PCD: 2023-11-15
Clinical trial
A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2011-2012, When Administered to Elderly SubjectsStatus: Completed, Estimated PCD: 2011-06-01
Clinical trial
A Phase 3, Randomised, Observer-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants 18-84 Years of Age in the United KingdomStatus: Completed, Estimated PCD: 2022-03-29